– USA, CA – Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis, today announced the appointment of Dave Amerson to its Board of Directors.
“Dave has established an unrivaled track record of successful commercialization of new medical device technologies. His unique perspective and experience bringing game-changing med-tech solutions to market are timely additions to our Board as we accelerate our commercialization of the MISHA Knee System in the United States. We are excited to welcome him to our Board,” said founder and CEO Dr. Anton Clifford.
About Dave Amerson
Amerson has over three decades of leadership experience and nearly $3 billion of M&A transactions in medical devices as a CEO or as an active board member. He served as President and CEO of NeoTract, Inc., which was acquired by Teleflex in 2017 in a transaction valued at up to $1.1 billion. In addition, Dave Amerson served on the Board of Directors for Relievant Medsytems, Inc., which was acquired by Boston Scientific Corporation in 2023 for an upfront cash payment of $850 million and undisclosed additional payments based on commercial milestones. He also served as Chairman of the Board of Palette Life Sciences, which was acquired by Teleflex in 2023 for an upfront cash payment of $600 million and an additional $50 million based on certain milestones.
“I am thrilled to join Moximed’s Board of Directors at this exciting point in the company’s commercial trajectory,” said Dave Amerson. “The parallels I see between Moximed and my experience successfully leading and advising other disruptive med-tech companies is compelling. Moximed has developed a unique, patient-centered solution to a massive clinical problem. The company reports excellent clinical outcomes, has FDA market authorization, and is now seeing tremendous surgeon and patient interest in the MISHA Knee System. I’m excited to work with Anton and the team to help more patients gain access to the technology and to similarly contribute to Moximed’s future success.”
About Moximed
Moximed’s technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis. With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss. Moximed is based in Fremont, California.
SOURCE: https://moximed.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
